Pediatric autoimmune myelofibrosis: Experience from a large pediatric tertiary care center
- PMID: 36661251
- DOI: 10.1002/pbc.30144
Pediatric autoimmune myelofibrosis: Experience from a large pediatric tertiary care center
Abstract
Autoimmune myelofibrosis (AIMF) is a rare disorder characterized by cytopenias and autoimmunity, with characteristic bone marrow findings that include lymphocytic infiltration and fibrosis. AIMF is described predominantly in adult populations who have systemic lupus erythematosis (SLE), with scant pediatric cases described mainly in older adolescents with SLE. Here, we described the largest single-center pediatric experience of pediatric autoimmune myelofibrosis (PAIMF) series, demonstrating both similarities and distinctions from the adult experience. Patients overall respond well to steroid therapy, but these patients were significantly younger, infrequently carried a diagnosis of SLE, and causative genetic lesions were identified in many cases.
© 2023 Wiley Periodicals LLC.
References
REFERENCES
-
- Piatek CI, Vergara-Lluri ME, Pullarkat V, et al. Autoimmune myelofibrosis: clinical features, course, and outcome. Acta Haematol. 2017;138(3):129-137.
-
- Marcellino B, El Jamal SM, Mascarenhas JO. Distinguishing autoimmune myelofibrosis from primary myelofibrosis. Clin Adv Hematol Oncol. 2018;16(9):619-626.
-
- Kvasnicka HM, Beham-Schmid C, Bob R, et al. Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study. Histopathology. 2016;68(6):905-915.
-
- DeLario MR, Sheehan AM, Ataya R, et al. Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis-an entity different from adults. Am J Hematol. 2012;87(5):461-464.
-
- Mishra P, Halder R, Aggarwal M, et al. Pediatric myelofibrosis: WHO 2024 update on myeloproliferative neoplasms calling. Pediatr Blood Cancer. 2020;67(5):e28232.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical